Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Note 7 - Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2026

	*Three Months Ended June 30,*						*Six Months Ended June 30,*
(in thousands, except for net income (loss) per share)	*2026*			*2025*			*2026*			*2025*
Numerator:
Net income (loss)	$	(5,313	)	$	(2,454	)	$	(9,206	)	$	(5,078	)

Denominator:
Weighted-average common shares outstanding, basic and diluted⁽¹⁾		8,542			6,998			8,539			6,993

Net income (loss) per common share, basic and diluted	$	(0.62	)	$	(0.35	)	$	(1.08	)	$	(0.73	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share
Stock options to purchase common stock		678			627			678			627
Unvested restricted stock units		145			128			145			128